|
Jul 4
|
Thermo Fisher Scientific (NYSE:TMO) Gains FDA Approval for Rapid Cancer Diagnostic Tool
|
|
Jul 4
|
Sodium Perborate Market worth $184.0 million in 2030, at 3.7%, says MarketsandMarkets™
|
|
Jul 4
|
Solventum Amends Thermo Fisher Deal, Retains Water Filtration Business
|
|
Jul 4
|
1 Large-Cap Stock to Own for Decades and 2 to Steer Clear Of
|
|
Jul 3
|
Thermo Fisher and Xcell Biosciences Partner to Advance TIL and Treg Cell Therapies
|
|
Jul 3
|
Biopharmaceuticals Manufacturing Consumables Testing Market 2025-2030: Thermo Fisher Scientific, Danaher Corporation, and Merck Lead
|
|
Jul 3
|
Here's What to Expect From Thermo Fisher Scientific's Next Earnings Report
|
|
Jul 2
|
Jim Cramer on Thermo Fisher: “It Does Seem Like it’s Bottoming”
|
|
Jul 1
|
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 23, 2025
|
|
Jul 1
|
Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights
|
|
Jun 30
|
From Agilent to ZEISS: SDi's 2025 Report Dissects Market Share and Growth Across 21 Lab Instrument Leaders
|
|
Jun 30
|
Wells Fargo Remains a Buy on Thermo Fisher (TMO) With a PT of $570
|
|
Jun 25
|
Thermo Fisher Scientific Awarded $94.5 Million DoD Contract for US Navy Dosimetry Systems
|
|
Jun 25
|
Oligonucleotide Synthesis Market Research and Global Forecast Report 2025-2030: Rising Emphasis on Advancing Drug Delivery and Scalable Synthesis Technologies for Oligonucleotide-Based Therapeutics
|
|
Jun 25
|
How Hologic Leverages Its Financial Firepower to Drive Long-Term Value
|
|
Jun 25
|
Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply
|
|
Jun 25
|
Thermo Fisher, Ethris Partner to Offer Integrated mRNA Solutions for Biopharma
|
|
Jun 24
|
Thermo Fisher Scientific Inc. (TMO): A Bull Case Theory
|
|
Jun 23
|
Thermo Fisher Scientific Awarded $94.5 Million U.S. Government Contract to Supply the Navy with Advanced Radiation Detection Systems
|
|
Jun 20
|
The past year for Thermo Fisher Scientific (NYSE:TMO) investors has not been profitable
|